Clinical Trial Update: Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating therapeutic plasma exchange alone or with ruxolitinib for COVID-19-associated cytokine release syndrome; study completed with results p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytokine Release Syndrome

Drugs mentioned

• Ruxolitinib (ruxolitinib)
• Therapeutic Plasma Exchange

Snippet

Sponsor: Prisma Health-Upstate | Conditions: Cytokine Release Syndrome, COVID19 | Phase 2 | Status: COMPLETED | Results posted: 2021-12-02